Core Viewpoint - The company plans to use bank acceptance bills and letters of credit to pay for part of the fundraising projects and will replace these payments with the raised funds, aiming to improve the efficiency of fund usage and reduce financial costs [1][7][9]. Fundraising Basic Situation - The company raised a total of RMB 75,438.20 million by issuing 51.67 million shares at RMB 14.60 per share, with actual funds received amounting to RMB 67,582.85 million after deducting issuance costs of RMB 7,855.35 million [1][2]. Fundraising Investment Project Situation - The company approved the use of RMB 57 million of excess funds to repay bank loans and made changes to the implementation of fundraising projects without altering the investment direction or total amount [2][3]. - The company has also approved the use of remaining funds from the "Kunshan Hanjing Precision Connector Production Project" for new projects, including "Semiconductor Metal Heat Sink Material Project" and "Automotive High-Frequency Signal Cable and Connector Project" [3][4]. Use of Bills and Letters of Credit - The company intends to use bank acceptance bills and letters of credit for payments, which will be replaced by the raised funds, following an internal approval process to ensure compliance and efficiency [6][7]. Impact on Daily Operations - The use of these financial instruments is expected to lower financial costs and enhance the flexibility of fund usage without affecting the normal progress of fundraising projects [7][9]. Approval Procedures and Opinions - The board and supervisory committee have reviewed and approved the use of bank acceptance bills and letters of credit, confirming that this does not change the direction of the raised funds and supports efficient fund usage [7][8].

Summary of Key Points Core Viewpoint - The company, Aibono Medical Technology Co., Ltd., is utilizing funds raised from a simplified issuance of shares to provide loans to its subsidiary, Tianyan Pharmaceutical, for the implementation of investment projects, ensuring compliance with regulatory requirements and maintaining the integrity of the fundraising purpose [1][4][5]. Fundraising Overview - The company plans to issue 3,593,615 shares at a price of 79.20 RMB per share, raising a total of 284,614,308 RMB, which will be used for specific investment projects [1][2]. - The total investment amount for the projects is 422,430,700 RMB, with 284,614,308 RMB allocated from the raised funds [2]. Investment Project Details - The funds will be allocated to various projects, with a total planned investment of 422,430,700 RMB, and the intended use of raised funds amounting to 284,614,308 RMB [2]. - The company may adjust the investment sequence and amounts based on project progress and funding needs, with any shortfall covered by self-raised funds [2]. Loan Provision to Subsidiary - The company intends to provide a loan of up to 260,000,000 RMB to Tianyan Pharmaceutical for the construction of an "invisible lens and injection mold processing production line" [3][4]. - The loan will be disbursed in batches based on project progress and actual funding needs, with interest rates determined by the latest published LPR [3][4]. Subsidiary Information - Tianyan Pharmaceutical, established on September 23, 2015, has a registered capital of 37,500,000 RMB and operates in pharmaceutical technology research and medical device production [3]. - As of December 31, 2024, Tianyan Pharmaceutical reported total assets of 541,571,200 RMB, total liabilities of 461,288,700 RMB, and a net profit of 7,607,000 RMB [3]. Purpose and Impact of the Loan - The loan aims to support the implementation of investment projects, aligning with the company's strategic planning and long-term interests without altering the intended use of raised funds [4][5]. - The management of the funds will adhere to strict regulatory protocols, ensuring effective oversight and compliance with relevant laws [4][5]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the loan provision, confirming that it meets legal and regulatory standards and aligns with the company's long-term development needs [5][6].

二、募集资金投资项目情况 公司首次公开发行股票募集资金净额为人民币 122,466.93 万元，计划募集资 金金额为人民币 120,000 万元，超额募集资金金额为人民币 2,466.93 万元。公司 首次公开发行股票募集资金投资项目如下： | 序号 项目名称 | 总投资额 | | 募集资金投入金额 | | | --- | --- | --- | --- | --- | | （万元） （万元） | | | | | | 合计 120,000.00 120,000.00 | | | | | | 十八次会议以及 2021 年 12 月 16 日召开的 2021 年第三次临时股东大会审议通过 | | | | | | 了《关于使用部分超募资金用于永久补充流动资金的议案》，同意公司使用超募 | | | | | | 740 29.9968%，用于 资金中的 万元用于永久补充流动资金，占超募资金总额的 | | | | | | 公司与主营业务相关的生产经营活动。具体内容详见 2021 年 12 月 1 | | 日披露于上 | | | | 海证券交易所网站（www.sse.com.cn）的《北京亿华通科技股份有限公司关于使 | ...

证券代码：688339 证券简称：亿华通 公告编号：2025-031 北京亿华通科技股份有限公司 关于使用部分超募资金归还银行贷款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京亿华通科技股份有限公司（以下简称公司）于 2025 年 5 月 29 日召开 第三届董事会第二十四次会议、第三届监事会第十九次会议审议通过了《关于 使用部分超募资金归还银行贷款的议案》，同意公司使用超募资金中的 740 万元 归还银行贷款，占超募资金总额的 29.9968%。本事项尚需提交公司股东大会审 议。 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意北京亿华通科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1447 号），公司获准向社会公 众公开发行人民币普通股 17,630,523 股，每股面值为人民币 1 元，每股发行价 格为人民币 76.65 元，募集资金总额为人民币 135,137.96 万元，扣除发行费用 后募集资金净额为人民币 122,466.93 万元。前述募集资金到位情况已经信永中 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-034 爱博诺德（北京）医疗科技股份有限公司 关于使用募集资金向控股子公司提供借款以实施募投 项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第二届董事会第十九次会议和第二届监事会第十六次会议，审议通过 《关于公司使用募集资金向控股子公司提供借款以实施募投项目的议案》，同意 公司使用募集资金向控股子公司江苏天眼医药科技股份有限公司（以下简称"天 眼医药"）提供不超过 26,000.00 万元的借款以实施募投项目。公司监事会对本事 项发表了明确的同意意见，保荐机构中国银河证券股份有限公司（以下简称"保 荐机构"）对本事项出具了明确的核查意见。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意爱博诺德（北京）医疗科技 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号）， 公司 2024 年度以简易程序向特 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-029 爱博诺德（北京）医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届监事 会第十六次会议通知及相关材料于 2025 年 5 月 23 日以电子邮件的方式发出。会 议于 2025 年 5 月 29 日在公司会议室以现场与通讯相结合方式召开，本次会议由 监事会主席王丹璇女士召集并主持，应出席的监事 3 人，实际出席的监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、 规章、规范性文件和《公司章程》等有关规定，会议形成的决议合法、有效。经 与会监事认真讨论，审议通过如下事项： 一、审议并通过《关于 2024 年年度利润分配方案的议案》 经与会监事认真审议，监事会认为：公司 2024 年年度利润分配方案充分考虑 了公司盈利情况、现金流状态及资金需求计划，结合了当前发展阶段、长远发展 规则及股东合理回报规划等各种 ...

天津久日新材料股份有限公司（以下简称公司）于 2025 年 5 月 27 日召开第 五届董事会第二十四次会议、第五届监事会第二十三次会议，审议通过《关于使 用部分募集资金向控股孙公司提供借款以实施募投项目的议案》，同意公司使用 募集资金 5,000.00 万元向控股孙公司湖南弘润化工科技有限公司（以下简称弘 润化工）提供借款，用于实施湖南弘润化工科技有限公司 8,000 吨/年光引发剂 H4 酮项目（以下简称弘润化工项目）。该事项在公司董事会审议权限范围内， 无需提交股东大会审议。公司监事会、保荐机构对该事项发表了同意的意见。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意天津久日新材料股份有限公司首次公 开发行股票注册的批复》（证监许可20191887 号），同意公司首次公开发行 股票的注册申请，公司向社会公开发行人民币普通股 2,780.68 万股，每股面值 人民币 1.00 元，每股发行价为人民币 66.68 元，共募集资金人民币 185,415.74 万元，扣除发行费用 14,486.45 万元（不含税），实际募集资金净额为人民币 验证，并出具了《天津久日新材料股份有限公司发行人民币普通股（ ...

Group 1 - The core point of the announcement is the approval of the use of part of the raised funds to provide a loan to the subsidiary for the implementation of a fundraising project [1][2] - The Supervisory Board meeting was held on May 27, 2025, with all three supervisors present, and the resolutions passed were deemed legal and effective [1] - The loan amount approved is RMB 50 million, with an interest rate aligned with the current bank loan rate, aimed at supporting the "Ultra-High Precision Drive and Control Integration R&D Project" [1][2] Group 2 - The decision to provide the loan is in accordance with the fundraising plan and does not harm the interests of the company or its shareholders, particularly minority shareholders [1] - The resolution complies with relevant regulations, including the "Regulatory Guidelines for the Management and Use of Raised Funds by Listed Companies" and the "Shanghai Stock Exchange Science and Technology Innovation Board Listing Rules" [1]

Group 1 - The stock price of Daqo Energy (688303.SH) has declined to 19.27 yuan, representing a drop of 1.98%, and is currently in a state of below the issue price [1] - Daqo Energy was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 22, 2021, with an initial public offering (IPO) price of 21.49 yuan per share, raising a total of 644.7 million yuan [1] - The company planned to use the raised funds for projects including the annual production of 1,000 tons of high-purity semiconductor materials and 35,000 tons of polysilicon, as well as for working capital [1] Group 2 - In 2022, Daqo Energy issued A-shares to specific investors, raising approximately 10.99 billion yuan at an issue price of 51.79 yuan per share [2] - The net proceeds from this issuance, after deducting issuance costs, amounted to about 10.94 billion yuan, which has been fully utilized by the end of 2023 [2] - The total amount raised by Daqo Energy from both fundraising activities is approximately 17.447 billion yuan [3]

天洋新材（上海）科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 天洋新材（上海）科技股份有限公司（以下简称"公司"）第四届监事会第二十五 次会议于 2025 年 05 月 26 日上午 11 时在公司二楼会议室以现场方式召开，本次会议应 出席监事 3 人，现场实际出席监事 3 人，董事会秘书及证券事务代表列席了本次会议。 会议由公司监事会主席郑晓燕女士主持。本次会议的召开符合《中华人民共和国公司法》 （以下简称"《公司法》"）、《天洋新材（上海）科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，会议合法、有效。 二、 监事会会议审议情况 （一）审议通过了《关于使用部分闲置募集资金暂时补充流动资金的议案》 证券代码：603330 证券简称：天洋新材 公告编号：2025-042 易所上市公司自律监管指引第 1 号——规范运作》等有关规定，结合 2022 年度非公开发 行募集资金投资项目的资金使用计划和项目的建设进度，公司在确保不影响募集资金投 资项目建设的前提下，为提高 ...